KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Non-Current Debt (2016 - 2025)

Abbott Laboratories' Non-Current Debt history spans 17 years, with the latest figure at $9.9 billion for Q4 2025.

  • For Q4 2025, Non-Current Debt fell 21.62% year-over-year to $9.9 billion; the TTM value through Dec 2025 reached $9.9 billion, down 21.62%, while the annual FY2025 figure was $9.9 billion, 21.62% down from the prior year.
  • Non-Current Debt for Q4 2025 was $9.9 billion at Abbott Laboratories, down from $11.6 billion in the prior quarter.
  • Across five years, Non-Current Debt topped out at $17.5 billion in Q2 2021 and bottomed at $9.9 billion in Q4 2025.
  • The 5-year median for Non-Current Debt is $14.5 billion (2022), against an average of $14.5 billion.
  • The largest annual shift saw Non-Current Debt grew 4.08% in 2021 before it dropped 21.62% in 2025.
  • A 5-year view of Non-Current Debt shows it stood at $17.3 billion in 2021, then fell by 16.04% to $14.5 billion in 2022, then fell by 6.36% to $13.6 billion in 2023, then fell by 7.16% to $12.6 billion in 2024, then decreased by 21.62% to $9.9 billion in 2025.
  • Per Business Quant, the three most recent readings for ABT's Non-Current Debt are $9.9 billion (Q4 2025), $11.6 billion (Q3 2025), and $12.9 billion (Q2 2025).